Last reviewed · How we verify
Juven
Juven is a Small molecule drug developed by The University of Texas Health Science Center at San Antonio. It is currently in Phase 1 development. Also known as: Conditionally essential amino acids.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Juven |
|---|---|
| Also known as | Conditionally essential amino acids |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds (PHASE2)
- Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery (EARLY_PHASE1)
- Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation (PHASE2)
- Trauma Screening and Supplementation (NA)
- Spine and Tumor Screening and Supplementation (NA)
- Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults (NA)
- Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer (PHASE3)
- Multimodal Treatment Strategy for Cancer Cachexia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Juven CI brief — competitive landscape report
- Juven updates RSS · CI watch RSS
- The University of Texas Health Science Center at San Antonio portfolio CI
Frequently asked questions about Juven
What is Juven?
Who makes Juven?
Is Juven also known as anything else?
What development phase is Juven in?
Related
- Manufacturer: The University of Texas Health Science Center at San Antonio — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Conditionally essential amino acids
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing